SCHEMBL772126

SCHEMBL772126

CC(C)(C)NC(=O)NCC(=O)N1CCC2CCCC=C2C1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KMT2A Q03164 2/20 0.35
POLB P06746 1/20 0.35
OPRD1 P41143 7/20 0.35
OPRM1 P35372 6/20 0.35
MEN1 O00255 1/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.34
OPRK1 P41145 4/20 0.34
THRA P10827 2/20 0.34
VDR P11473 1/20 0.34
HTT P42858 1/20 0.33
RAB9A P51151 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
CACNA1H O95180 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770590 0.89 HTT (0.37) ALDH1A1CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL771027 0.86 PPID (0.35) ALDH1A1KMT2APOLBMEN1TSHR
SCHEMBL770227 0.85 LMNA (0.34) ALDH1A1KMT2APOLBLMNADPP8
SCHEMBL15380799 0.82 EPHX1 (0.46) ALDH1A1TSHRRAB9A
SCHEMBL771006 0.82 EPHX1 (0.46) ALDH1A1TSHRRAB9A
SCHEMBL770820 0.81 ALDH1A1 (0.36) ALDH1A1CYP2C9CYP2C19KMT2ALMNA
SCHEMBL770365 0.80 BRD4 (0.44) ALDH1A1NPSR1KMT2APOLBMEN1
SCHEMBL770993 0.79 PPID (0.48) NPSR1KMT2AMEN1
SCHEMBL15378143 0.78 NPC1 (0.47) ALDH1A1LMNAHTTRAB9ADPP8
SCHEMBL770460 0.78 EPHX2 (0.45) ALDH1A1KMT2ALMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885CYP2D6 395/4885CYP2C9 303/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885CYP2D6 394/4885CYP2C9 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.